Abstract:The uptake and efflux of solutes across a plasma membrane is controlled by transporters. There are two main superfamilies of transporters, adenosine 5′-triphosphate (ATP) binding cassettes (ABCs) and solute carriers (SLCs). In the brain, SLC transporters are involved in transporting various solutes across the blood–brain barrier, blood–cerebrospinal fluid barrier, astrocytes, neurons, and other brain cell types including oligodendrocytes and microglial cells. SLCs play an important role in maintaining normal brain function. Hence, mutations in the genes that encode SLC transporters can cause a variety of neurological disorders. We identified the following SLC gene variants in 25 patients in our cohort: SLC1A2, SLC2A1, SLC5A1, SLC6A3, SLC6A5, SLC6A8, SLC9A6, SLC9A9, SLC12A6, SLC13A5, SLC16A1, SLC17A5, SLC19A3, SLC25A12, SLC25A15, SLC27A4, SLC45A1, SLC46A1, and SLC52A3. Eight patients harbored pathogenic or likely pathogenic mutations (SLC5A1, SLC9A6, SLC12A6, SLC16A1, SLC19A3, and SLC52A3), and 12 patients were found to have variants of unknown clinical significance (VOUS); these variants occurred in 11 genes (SLC1A2, SLC2A1, SLC6A3, SLC6A5, SLC6A8, SLC9A6, SLC9A9, SLC13A5, SLC25A12, SLC27A4, and SLC45A1). Five patients were excluded as they were carriers. In the remaining 20 patients with SLC gene variants, we identified 16 possible distinct neurological disorders. Based on the clinical presentation, we categorized them into genes causing intellectual delay (ID) or autism spectrum disorder (ASD), those causing epilepsy, those causing vitamin-related disorders, and those causing other neurological diseases. Several variants were detected that indicated possible personalized therapies: SLC2A1 led to dystonia or epilepsy, which can be treated with a ketogenic diet; SLC6A3 led to infantile parkinsonism-dystonia 1, which can be treated with levodopa; SLC6A5 led to hyperekplexia 3, for which unnecessary treatment with antiepileptic drugs should be avoided; SLC6A8 led to creatine deficiency syndrome type 1, which can be treated with creatine monohydrate; SLC16A1 led to monocarboxylate transporter 1 deficiency, which causes seizures that should not be treated with a ketogenic diet; SLC19A3 led to biotin-thiamine-responsive basal ganglia disease, which can be treated with biotin and thiamine; and SLC52A3 led to Brown-Vialetto-Van-Laere syndrome 1, which can be treated with riboflavin. The present study examines the prevalence of SLC gene mutations in our cohort of children with epilepsy and other neurological disorders. It highlights the diverse phenotypes associated with mutations in this large family of SLC transporter proteins, and an opportunity for personalized genomics and personalized therapeutics.

Sleep Abnormalities in SLC13A5 Citrate Transporter Disorder

Autosomal Dominant Sleep-Related Hypermotor Epilepsy Associated with a Novel Mutation of KCNT1.

Subjective sleep assessment in individuals with SYNGAP1-associated syndrome

Characterization of sleep in a mouse model of CLN3 disease revealed sex-specific sleep disturbances

Molecular phenotypes segregate missense mutations in SLC13A5 Epilepsy

Untargeted Metabolomics of Slc13a5 Deficiency Reveal Critical Liver–Brain Axis for Lipid Homeostasis

A draft conceptual model of SLC6A1 neurodevelopmental disorder

The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization

424 Clinical Translational Approach to Targeted Therapy in SLC6A1-related Neurodevelopmental Disorder

A clinical-translational review of sleep problems in neurodevelopmental disabilities

1147 Sleep Enigmas in Primary Ciliary Dyskinesia: An Atypical Case of Sleep Movement Disorders and Alpha-Delta Sleep

0258 Altered sleep regulation in a mouse model of Parkinson’s disease

A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism

Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier

Novel Approaches to Studying SLC13A5 Disease

Deficiency of Autism-Related Scn2a Gene in Mice Disrupts Sleep Patterns and Circadian Rhythms

Connectomic and behavioral alterations in creatine transporter deficiency are partially normalized by gene therapy

0828 Investigation of Sleep Disturbances in Pediatric Patients with Septo-Optic Dysplasia

SLC gene mutations and pediatric neurological disorders: diverse clinical phenotypes in a Saudi Arabian population

Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity

Clinical Study of Sleep Related Rhythmic Movement Disorder